{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:28:59Z","timestamp":1793651339000,"version":"4.5.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.amjmed.2026.06.034","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:07:55Z","timestamp":1785856075000},"page":"1640-1652.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between PCSK9 targeted therapy and the risk of stroke and dementia: A meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2021-1660","authenticated-orcid":false,"given":"Vikash","family":"Jaiswal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Novonil","family":"Deb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fakhar","family":"Latif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhigan Babu","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi","family":"Garimella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishat","family":"Shama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahas Reddy","family":"Jitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidra","family":"Naz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Perone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishanth","family":"Mattumpuram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song Peng","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.amjmed.2026.06.034_bib0001","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.amjmed.2026.06.034_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810221","article-title":"Recent advances on the roles of PCSK-9 inhibitors in the management of acute ischemic stroke patients","volume":"23","author":"Ilut","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.amjmed.2026.06.034_bib0003","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.amjmed.2026.06.034_bib0004","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)","volume":"74","author":"Koskinas","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2026.06.034_bib0005","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejim.2020.11.021","article-title":"Proprotein Convertase Subtilisin-Kexin type 9 inhibitors and stroke prevention: a meta-analysis","volume":"85","author":"Sagris","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.amjmed.2026.06.034_bib0006","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.amjmed.2026.06.034_bib0007","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.mayocp.2025.01.018","article-title":"Impact of lipid-lowering combination therapy with Statins and Ezetimibe versus Statin monotherapy on the reduction of cardiovascular outcomes: a meta-analysis","volume":"100","author":"Banach","year":"2025","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.amjmed.2026.06.034_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.102198","article-title":"Implantable cardioverter defibrillators for primary prevention in patients with ischemic and non-ischemic cardiomyopathy: a meta-analysis","volume":"49","author":"Jaiswal","year":"2024","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"10.1016\/j.amjmed.2026.06.034_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.102154","article-title":"Association between catheter ablation and dementia among patients with atrial fibrillation: a systematic review and meta-analysis","volume":"49","author":"Jaiswal","year":"2024","journal-title":"Curr Probl Cardiol"},{"issue":"11","key":"10.1016\/j.amjmed.2026.06.034_bib0010","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.amjmed.2026.06.034_bib0011","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I2 is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.amjmed.2026.06.034_bib0012","series-title":"Stata Statistical Software: Release 18","year":"2023"},{"issue":"22","key":"10.1016\/j.amjmed.2026.06.034_bib0013","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2026.06.034_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2017.09.007","article-title":"A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)","volume":"12","author":"Koh","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.amjmed.2026.06.034_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"issue":"43","key":"10.1016\/j.amjmed.2026.06.034_bib0016","doi-asserted-by":"crossref","first-page":"ehv370","DOI":"10.1093\/eurheartj\/ehv370","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.amjmed.2026.06.034_bib0017","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of Evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2026.06.034_bib0018","year":"2019"},{"issue":"18","key":"10.1016\/j.amjmed.2026.06.034_bib0019","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2026.06.034_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2019.10.015","article-title":"ODYSSEY EAST: alirocumab efficacy and safety versus ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand","volume":"14","author":"Han","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"16","key":"10.1016\/j.amjmed.2026.06.034_bib0021","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.amjmed.2026.06.034_bib0022","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.amjmed.2026.06.034_bib0023","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.amjmed.2026.06.034_bib0024","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1253\/circj.CJ-19-0412","article-title":"Effect of Alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndrome \u2015 the ODYSSEY J-IVUS trial \u2015","volume":"83","author":"Ako","year":"2019","journal-title":"Circ J"},{"issue":"4","key":"10.1016\/j.amjmed.2026.06.034_bib0025","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1536\/ihj.22-052","article-title":"Effect of the early application of Evolocumab on blood lipid profile and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome","volume":"63","author":"Hao","year":"2022","journal-title":"Int Heart J"},{"key":"10.1016\/j.amjmed.2026.06.034_bib0026","series-title":"A Double-Blind,Randomized, Placebo-Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Evolocumab (AMG 145) on LDL-C in Subjects With Type 2 Diabetes Mellitus and Hypercholesterolemia\/Mixed Dyslipidemia","year":"2018"},{"key":"10.1016\/j.amjmed.2026.06.034_bib0027","series-title":"A Double-Blind,Randomized, Placebo-Controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Combination With Statin Therapy in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia (BERSON)","year":"2019"},{"key":"10.1016\/j.amjmed.2026.06.034_bib0028","series-title":"A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Long-Term Tolerability and Durable Efficacy of AMG 145 (Evolocumab) on LDL-C in Hyperlipidemic Subjects","year":"2022"},{"key":"10.1016\/j.amjmed.2026.06.034_bib0029","series-title":"A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Subject With Heterozygous Familial Hypercholesterolemia","year":"2022"},{"issue":"10","key":"10.1016\/j.amjmed.2026.06.034_bib0030","article-title":"Neurocognitive impairment in cardiovascular disease patients taking statins versus Proprotein Convertase Subtilisin\/Kexin type 9 (PCSK9) inhibitors: a systematic review","volume":"14","author":"Shahid","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.amjmed.2026.06.034_bib0031","doi-asserted-by":"crossref","DOI":"10.1177\/2042098620959271","article-title":"Neurocognitive effects associated with proprotein convertase subtilisin-kexin type 9 inhibitor use: a narrative review","volume":"12","author":"Yuet","year":"2021","journal-title":"Ther Adv Drug Saf"},{"issue":"5","key":"10.1016\/j.amjmed.2026.06.034_bib0032","doi-asserted-by":"crossref","first-page":"164","DOI":"10.18773\/austprescr.2016.060","article-title":"PCSK9 inhibitors \u2013 mechanisms of action","volume":"39","author":"Page","year":"2016","journal-title":"Aust Prescr"},{"issue":"14","key":"10.1016\/j.amjmed.2026.06.034_bib0033","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"Lloyd-Jones","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"10106","key":"10.1016\/j.amjmed.2026.06.034_bib0034","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"10.1016\/j.amjmed.2026.06.034_bib0035","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","article-title":"The evolving future of PCSK9 inhibitors","volume":"72","author":"Rosenson","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.amjmed.2026.06.034_bib0036","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1161\/STR.0000000000000430","article-title":"Cognitive impairment after ischemic and hemorrhagic Stroke: a scientific statement from the American Heart Association\/American Stroke Association","volume":"54","author":"El Husseini","year":"2023","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.amjmed.2026.06.034_bib0037","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1161\/STR.0b013e3182299496","article-title":"Vascular contributions to cognitive impairment and dementia","volume":"42","author":"Gorelick","year":"2011","journal-title":"Stroke"},{"issue":"16","key":"10.1016\/j.amjmed.2026.06.034_bib0038","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of Alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.amjmed.2026.06.034_bib0039","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCULATIONAHA.117.029785","article-title":"PCSK9 Variants, low-density lipoprotein cholesterol, and neurocognitive impairment","volume":"137","author":"Mefford","year":"2018","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.amjmed.2026.06.034_bib0040","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of Evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.amjmed.2026.06.034_bib0041","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014400","article-title":"Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: a frequentist network meta-analysis","volume":"98","author":"Zhao","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.amjmed.2026.06.034_bib0042","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030714","article-title":"Lipid-lowering therapy and risk of hemorrhagic stroke: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"B\u00e9trisey","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.amjmed.2026.06.034_bib0043","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/CIRCULATIONAHA.112.145334","article-title":"Statins as antithrombotic drugs","volume":"127","author":"Violi","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2026.06.034_bib0044","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.biopha.2018.09.164","article-title":"No effect of PCSK9 inhibitors on D-dimer and fibrinogen levels in patients with familial hypercholesterolemia","volume":"108","author":"Schol-Gelok","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"10.1016\/j.amjmed.2026.06.034_bib0045","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jacc.2022.05.041","article-title":"Mendelian randomization study of PCSK9 and HMG-CoA reductase inhibition and cognitive function","volume":"80","author":"Rosoff","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"16\u201318","key":"10.1016\/j.amjmed.2026.06.034_bib0046","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1089\/ars.2024.0674","article-title":"Cholesterol metabolism in neurodegenerative diseases","volume":"41","author":"He","year":"2024","journal-title":"Antioxid Redox Signal"},{"issue":"9","key":"10.1016\/j.amjmed.2026.06.034_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e30523","article-title":"The intersection of cerebral cholesterol metabolism and Alzheimer\u2019s disease: mechanisms and therapeutic prospects","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"},{"issue":"s1","key":"10.1016\/j.amjmed.2026.06.034_bib0048","doi-asserted-by":"crossref","first-page":"S371","DOI":"10.3233\/JAD-240388","article-title":"Hypercholesterolemia and Alzheimer\u2019s disease: unraveling the connection and assessing the efficacy of lipid-lowering therapies","volume":"101","author":"Pappolla","year":"2024","journal-title":"J Alzheimers Dis JAD"},{"issue":"9","key":"10.1016\/j.amjmed.2026.06.034_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2023.100426","article-title":"PCSK9 and the nervous system: a no-brainer?","volume":"64","author":"Jaafar","year":"2023","journal-title":"J Lipid Res"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326005103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326005103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:56:49Z","timestamp":1793649409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934326005103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0002934326005103"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.06.034","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between PCSK9 targeted therapy and the risk of stroke and dementia: A meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.06.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}